PMC5841933_01
Clinical course and neutrophils count in relationship with drugs administration.
mjhid-10-1-e2018019f1.jpg
PMC5841933_01_mjhid-10-1-e2018019f1.jpg
f1-mjhid-10-1-e2018019
The patient (Figure 1) was treated according to the local standard of care for low risk HL using 2 cycles of OEPA (vincristine 1.5 mg/m2/dose IV days 1, 8 and 15, etoposide 125 mg/m2/dose IV days 1-5, prednisone 60 mg/m2/day PO days 1-15, and doxorubicin 40 mg/m2 IV days 1 and 15) chemotherapy only.